Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
Explore this paper's citation graph
Summary
These risks are described, specific recommendations concerning vascular access, stent choice, concomitant use of proton-pump inhibitors and the use and duration of triple therapy following stent placement are provided based upon the risk assessment.
- Type
- article
- Published
- 2011-07-25
- Cited by
- 216
- References
- 103
- OpenAlex
- https://openalex.org/W1947134634
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:39414486
Keywords
Medicine, Antithrombotic, Clopidogrel, Atrial fibrillation, Aspirin
References
- Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
- Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
- Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
- A risk score to predict bleeding in patients with acute coronary syndromes.
- Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
- Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
- 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)
- Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta‐analysis
- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
- The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions.
- Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
- Ticlopidine versus oral anticoagulation for coronary stenting.
- Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.
- Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial.
- Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
- Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes
- Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
- New oral anticoagulant drugs in cardiovascular disease
Cited by
- Horse versus rabbit antithymocyte globulin in aplastic anemia.
- Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation in coronary stenting
- A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
- Apixaban after Acute Coronary Syndrome
- Safety and efficacy of transcatheter left atrial appendage closure using the Watchman device in Egyptian patients with nonvalvular atrial fibrillation
- Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
- Highlights and hot topics from 2011 in Thrombosis and Haemostasis
- In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry.
- Patients with atrial fibrillation undergoing percutaneous coronary intervention: current concepts and concerns: part II.
- Neue Antikoagulantien zur Schlaganfallprävention bei Patienten mit Vorhofflimmern
- Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk‐Score Acronyms (CHADS2, CHA2DS2‐VASc, R2CHADS2, HAS‐BLED, ATRIA, and More)
- Bleeding risk assessment and management in atrial fibrillation patients
- Bleeding risk assessment and management in atrial fibrillation patients.
- Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta‐analysis of 16 Clinical Trials and 9185 Patients
- One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry
- [Non-VKA oral anticoagulants: an update for the clinical biologists].
- Practical experience with ticagrelor: an Australian and New Zealand perspective
- Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations
- Comparative Analysis of the Effects of Three Antithrombotic Regimens on Clinical Outcomes of Patients with Atrial Fibrillation and Recent Percutaneous Coronary Intervention with Stent. A Retrospective Cohort Study
- Mild renal disease increases major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting
Related papers
- Effect of plasma protein binding on the anticoagulant action of warfarin in rats.
- Differential Effects of Esomeprazole on the Antiplatelet Activity of Clopidogrel in Healthy Individuals and Patients after Coronary Stent Implantation
- Studies on Anticoagulant and Antithrombotic Effects of Recombinant Hirudin-III
- Drug focus on warfarin — an anticoagulant medication
- Biologic responses to antithrombotic, anticoagulant, or fibrinolytic agents may differ in elderly patients.
- Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp)
- Warfarin reversal
- New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).